Wall Street analysts’ estimates

Wall Street analysts expect Merck & Co.’s (MRK) top line to increase 7.1% to $10.1 billion for 1Q18, compared to revenues of $9.4 billion for 1Q17.

Wall Street Recommendations for Merck & Co. before Earnings

The above chart shows analysts’ recommendations over the last 12 months. The revenues for Merck are expected to be driven by strong sales of Keytruda and other products, partially offset by lower sales of Remicade, Zetia, Vytorin.

Analysts’ ratings

Merck & Co.’s stock price has decreased nearly 4.9% over the last 12 months, but it increased ~5.7% in 2018 year-to-date. Analysts’ estimates show that the stock has a potential to return ~15.6% over the next 12 months. Wall Street analysts’ recommendations show a 12-month target price of $68.75 per share, compared to the last price of $59.47 per share as of April 29.

Analysts’ recommendations

Twenty-one analysts are tracking Merck & Co. Of these 21 analysts, six recommend a “strong buy,” ten recommend a “buy,” and five recommend a “hold” while none of the analysts recommend a “sell.”

The consensus rating for Merck & Co. stands at 1.95, which represents a “buy” for both long-term growth investors and value investors.

Merck’s valuation

Merck & Co. is trading at a forward PE multiple of 13.8x, which is higher than the industry average of ~12.4x. Also, Merck & Co. is trading at a forward EV-to-EBITDA (enterprise value to earnings before interest, tax, depreciation, and amortization) multiple of ~11.3x, which is lower than the industry average of ~11.8x.

The First Trust NASDAQ Pharmaceuticals ETF (FTXH) invests 4.5% of its portfolio in Merck & Co. (MRK).

Check out all the data we’ve added to our quote pages. Now you can get a valuation snapshot, earnings and revenue estimates, and historical data as well as dividend info. Take a look!

Latest articles

Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.

The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.

Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.

Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.

14 Jun

IEA Again Slashes Its Oil Demand Growth Estimate

WRITTEN BY Rabindra Samanta

As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.

14 Jun

Why Kimberly-Clark Stock May Stop Rising

WRITTEN BY Amit Singh

Kimberly-Clark (KMB) stock has risen 20.5% this year, boosted by the company’s better-than-expected sales and earnings during its last reported quarter. However, its stock could stop climbing. Here's why.

172.31.59.107